IDEXX Working Capital vs Cost of Revenue Analysis
IDXX Stock | USD 477.79 0.45 0.09% |
IDEXX Laboratories financial indicator trend analysis is infinitely more than just investigating IDEXX Laboratories recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether IDEXX Laboratories is a good investment. Please check the relationship between IDEXX Laboratories Working Capital and its Cost Of Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.
Working Capital vs Cost Of Revenue
Working Capital vs Cost of Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of IDEXX Laboratories Working Capital account and Cost of Revenue. At this time, the significance of the direction appears to have no relationship.
The correlation between IDEXX Laboratories' Working Capital and Cost of Revenue is 0.0. Overlapping area represents the amount of variation of Working Capital that can explain the historical movement of Cost of Revenue in the same time period over historical financial statements of IDEXX Laboratories, assuming nothing else is changed. The correlation between historical values of IDEXX Laboratories' Working Capital and Cost of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Working Capital of IDEXX Laboratories are associated (or correlated) with its Cost of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost of Revenue has no effect on the direction of Working Capital i.e., IDEXX Laboratories' Working Capital and Cost of Revenue go up and down completely randomly.
Correlation Coefficient | 0.0 |
Relationship Direction | Flat |
Relationship Strength | Insignificant |
Working Capital
The difference between a company’s current assets and current liabilities, indicating the liquidity and operational efficiency of the business.Cost Of Revenue
Cost of Revenue is found on IDEXX Laboratories income statement and represents the costs associated with goods and services IDEXX Laboratories provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most indicators from IDEXX Laboratories' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into IDEXX Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.At this time, IDEXX Laboratories' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 44.60 in 2024, whereas Selling General Administrative is likely to drop slightly above 194 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.9B | 2.0B | 2.2B | 2.3B | Total Revenue | 3.2B | 3.4B | 3.7B | 3.8B |
IDEXX Laboratories fundamental ratios Correlations
Click cells to compare fundamentals
IDEXX Laboratories Account Relationship Matchups
High Positive Relationship
High Negative Relationship
IDEXX Laboratories fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.8B | 2.3B | 2.4B | 2.7B | 3.3B | 3.4B | |
Other Current Liab | 322.9M | 415.6M | 458.9M | 433.7M | 478.7M | 502.6M | |
Total Current Liabilities | 725.3M | 582.8M | 763.6M | 1.2B | 951.5M | 999.1M | |
Total Stockholder Equity | 177.5M | 632.1M | 690.0M | 608.7M | 1.5B | 1.6B | |
Property Plant And Equipment Net | 533.8M | 555.2M | 587.7M | 649.5M | 702.2M | 737.3M | |
Net Debt | 897.3M | 524.6M | 779.2M | 1.2B | 493.9M | 255.9M | |
Retained Earnings | 1.6B | 2.2B | 2.9B | 3.6B | 4.4B | 4.7B | |
Accounts Payable | 72.2M | 74.6M | 116.1M | 110.2M | 110.6M | 116.2M | |
Cash | 90.3M | 383.9M | 144.5M | 112.5M | 453.9M | 476.6M | |
Non Current Assets Total | 1.2B | 1.2B | 1.5B | 1.6B | 1.8B | 1.9B | |
Non Currrent Assets Other | 299.0M | 337.2M | 397.4M | 425.6M | 448.5M | 470.9M | |
Cash And Short Term Investments | 90.3M | 383.9M | 144.5M | 112.5M | 453.9M | 476.6M | |
Net Receivables | 269.3M | 331.4M | 368.3M | 400.6M | 457.4M | 480.3M | |
Common Stock Shares Outstanding | 87.5M | 86.7M | 86.6M | 84.6M | 84.0M | 94.9M | |
Liabilities And Stockholders Equity | 1.8B | 2.3B | 2.4B | 2.7B | 3.3B | 3.4B | |
Inventory | 195.0M | 209.9M | 269.0M | 367.8M | 380.3M | 399.3M | |
Other Current Assets | 125.0M | 137.5M | 173.8M | 220.5M | 203.6M | 213.8M | |
Other Stockholder Equity | (1.4B) | (1.5B) | (2.2B) | (2.9B) | (2.9B) | (2.8B) | |
Total Liab | 1.7B | 1.7B | 1.7B | 2.1B | 1.8B | 1.9B | |
Total Current Assets | 679.6M | 1.1B | 955.7M | 1.1B | 1.5B | 1.6B | |
Non Current Liabilities Total | 929.3M | 1.1B | 983.6M | 902.2M | 823.8M | 865.0M | |
Intangible Assets | 58.5M | 52.5M | 99.0M | 97.7M | 84.5M | 74.5M | |
Short Long Term Debt Total | 987.7M | 908.5M | 923.7M | 1.3B | 947.9M | 995.3M | |
Short Term Debt | 288.8M | 50.0M | 148.5M | 654.0M | 325.0M | 208.6M | |
Property Plant And Equipment Gross | 614.5M | 646.3M | 1.3B | 649.5M | 1.6B | 1.7B | |
Accumulated Other Comprehensive Income | (46.2M) | (53.6M) | (53.5M) | (77.8M) | (71.2M) | (67.6M) | |
Common Stock Total Equity | 10.6M | 10.6M | 10.7M | 10.7M | 12.3M | 9.0M | |
Common Stock | 10.6M | 10.6M | 10.7M | 10.7M | 10.8M | 9.2M | |
Other Assets | 240.2M | 676.7M | 893.9M | 387.5M | 445.6M | 467.9M | |
Treasury Stock | (2.3B) | (2.6B) | (2.8B) | (3.6B) | (3.2B) | (3.1B) | |
Property Plant Equipment | 533.8M | 555.2M | 587.7M | 649.5M | 746.9M | 784.2M | |
Current Deferred Revenue | 41.5M | 42.6M | 40.0M | 37.9M | 37.2M | 25.0M | |
Good Will | 239.7M | 243.3M | 359.3M | 361.8M | 366.0M | 206.0M | |
Other Liab | 162.8M | 220.5M | 208.4M | 106.6M | 122.6M | 83.3M | |
Long Term Debt | 698.9M | 858.5M | 775.2M | 694.4M | 622.9M | 380.8M | |
Net Tangible Assets | (120.7M) | 336.2M | 690.0M | 149.3M | 134.3M | 141.1M | |
Noncontrolling Interest In Consolidated Entity | 264K | 280K | 352K | 707K | 813.1K | 853.7K | |
Retained Earnings Total Equity | 1.6B | 2.2B | 2.9B | 3.6B | 4.1B | 4.3B | |
Long Term Debt Total | 698.9M | 858.5M | 775.2M | 694.4M | 798.5M | 502.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.121 | Earnings Share 10.04 | Revenue Per Share 44.073 | Quarterly Revenue Growth 0.088 | Return On Assets 0.2283 |
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.